biotech · Glanzmann Thrombasthenia · Von Willebrand Disease (VWD) · COAG
Hemab Therapeutics Holdings
Hemab Therapeutics Holdings patent portfolio — 0 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- frederiksberg, DK
- Founded
- 2020
- Employees
- 90
- Programs
- 4
- Drugs
- 0
- Patents
- 0
Hemab Therapeutics Holdings patents
0 pharmaceutical patents indexed for Hemab Therapeutics Holdings. 0 expire within 24 months.
Hemab Therapeutics Holdings has 0 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
No patents matched
Frequently asked questions
How many patents does Hemab Therapeutics Holdings have?
0 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Hemab Therapeutics Holdings patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.